Antihypertensive Medications and the Risk of Sepsis

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Other angiotensin-receptor blockers (ARBs); Drug: Other major antihypertensive medication classes; Drug: Telmisartan; Drug: Angiotensin-converting enzyme inhibitors (ACEIs)

Study type: Observational

Funder types: Industry

Identifiers

NCT02248896

502.590

Details and patient eligibility

About

The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with the other major antihypertensive classes, including ACEIs, beta-blockers, CCBs and thiazide diuretics. A secondary objective was to assess whether the use of ARBs and ACEIs, compared with the other three major antihypertensive classes and with untreated hypertension, is associated with an increased risk of sepsis. A third objective was to evaluate whether the use of telmisartan compared with other ARBs, ACEIs and other major antihypertensive classes is associated with an increased risk of worse outcomes due to sepsis, in particular acute kidney injury and death

Enrollment: 1,129,062 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients, 18 years or older, with at least two-year follow-up in United Kingdom's general practice research database (GPRD), who had a diagnosis of or treatment for hypertension

Exclusion criteria

• Sepsis, chronic renal failure or on dialysis in the two-year period prior to cohort entry

Trial design

1,129,062 participants in 1 patient group

Hypertensive patients

Description:

Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data

Treatment:

Drug: Other angiotensin-receptor blockers (ARBs)

Drug: Other major antihypertensive medication classes

Drug: Telmisartan

Drug: Angiotensin-converting enzyme inhibitors (ACEIs)